Stem Cell Therapy Treatment for Muscular Dystrophy with MR by Dr Alok Sharma Mumbai India
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Muscular Dystrophy with MR by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. ...
By: neurogenbsi
Original post:
Stem Cell Therapy Treatment for Muscular Dystrophy with MR by Dr Alok Sharma Mumbai India - Video
Neil #39;s Story - Stem Cell Treatment = 25k, a Hug = Priceless
Neil #39;s battle to raise 25k for his stem cell treatment that will hopefully one day enable him to hug his three beautiful children again. http://www.neilsstory.co.u...
By: John Geary
See the original post:
Neil's Story - Stem Cell Treatment = £25k, a Hug = Priceless - Video
Neil #39;s Story (Mobile Version) - Stem Cell Treatment = 25k, a Hug = Priceless
Neil #39;s battle to raise 25k for his stem cell treatment that will hopefully one day enable him to hug his three beautiful children again. http://www.neilsstory.co.u...
By: John Geary
Read more here:
Neil's Story (Mobile Version) - Stem Cell Treatment = £25k, a Hug = Priceless - Video
NewsLife Interview: Dr. Theresa Deischer, Founder, SCPI- benefits and effects of stem cell therapy
NewsLife Interview: Dr. Theresa Deischer, Founder, Sound Choice Pharmaceutical Institute - benefits and effects of stem cell therapy - [May 7, 2013] For more...
By: PTV PH
Here is the original post:
NewsLife Interview: Dr. Theresa Deischer, Founder, SCPI- benefits and effects of stem cell therapy - Video
Hma-Qubec is working with members of Montreal's black community to increase the number of blood and stem cell donors.
Qubc's black community is chronically underrepresented in blood banks and on the bone marrow transplant registry, making treatment more challenging for black patients.
"A lot of times people suffer from sickle cell anemia, and there are not enough donors from our ethnicity that give, so I think it's just a good way of helping out other people," said Mitchum Burnett, who gave blood for the fifth time on Friday.
He discovered all it takes is a cheek swab to register as a stem cell donor.
Yet of more than 39,000 Quebecers registered as stem cell donors, only 89 are black Quebecers.
Tamu Townsend got involved in drives like the one held on Friday after her brother Emru was diagnosed with leukemia. He died after a long-sought transplant didn't work.
"One thing I realized was drives for blood and for stem cells increase a lot of awareness," Townsend said. "In fact, I'm registered as a stem cell donor because of my brother's illness."
Naderge Ceneston, a nurse with Hma-Qubec who is also black, said people in the black community need to be educated, to know how critical is to become blood and stem cell donors.
"We still have work to do to let them know that when they come to give blood, it's to give for their community first," Ceneston said.
Continued here:
Héma-Québec appeals for more black stem cell donors
Public release date: 10-May-2013 [ | E-mail | Share ]
Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles
Led by Dr. Peiyee Lee and Dr. Richard Gatti, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have used induced pluripotent stem (iPS) cells to advance disease-in-a-dish modeling of a rare genetic disorder, ataxia telangiectasia (A-T).
Their discovery shows the positive effects of drugs that may lead to effective new treatments for the neurodegenerative disease. iPS cells are made from patients' skin cells, rather than from embryos, and they can become any type of cells, including brain cells, in the laboratory. The study appears online ahead of print in the journal Nature Communications.
People with A-T begin life with neurological deficits that become devastating through progressive loss of function in a part of the brain called the cerebellum, which leads to severe difficulty with movement and coordination. A-T patients also suffer frequent infections due to their weakened immune systems and have an increased risk for cancer. The disease is caused by lost function in a gene, ATM, that normally repairs damaged DNA in the cells and preserves normal function.
Developing a human neural cell model to understand A-T's neurodegenerative process and create a platform for testing new treatments was critical because the disease presents differently in humans and laboratory animals. Scientists commonly use mouse models to study A-T, but mice with the disease do not experience the more debilitating effects that humans do. In mice with A-T, the cerebellum appears normal and they do not exhibit the obvious degeneration seen in the human brain.
Lee and colleagues used iPS cellderived neural cells developed from skin cells of A-T patients with a specific type of genetic mutation to create a disease-in-a-dish model. In the laboratory, researchers were able to model the characteristics of A-T, such as the cell's lack of ATM protein and its inability to repair DNA damage. The model also allowed the researchers to identify potential new therapeutic drugs, called small molecule read-through (SMRT) compounds, that increase ATM protein activity and improve the model cells' ability to repair damaged DNA.
"A-T patients with no ATM activity have severe disease but patients with some ATM activity do much better," Lee said. "This makes our discovery promising, because even a small increase in the ATM activity induced by the SMRT drug can potentially translate to positive effects for patients, slowing disease progression and hopefully improving their quality of life."
These studies suggest that SMRT compounds may have positive effects on all other cell types in the body, potentially improving A-T patients' immune function and decreasing their susceptibility to cancer.
Additionally, the patient-specific iPS cellderived neural cells in this study combined with the SMRT compounds can be an invaluable tool for understanding the development and progression of A-T. This iPS cellneural cell A-T disease model also can be a platform to identify more potent SMRT drugs. The SMRT drugs identified using this model can potentially be applied to most other genetic diseases with the same type of mutations.
Visit link:
UCLA stem cell researchers move toward treatment for rare genetic nerve disease
Public release date: 9-May-2013 [ | E-mail | Share ]
Contact: Andy Hoang ahoang@salk.edu 619-861-5811 Salk Institute
LA JOLLA, CA Scientists have long known that control mechanisms known collectively as epigenetics play a critical role in human development, but they did not know precisely how alterations in this extra layer of biochemical instructions in DNA contribute to development.
Now, in the first comprehensive analysis of epigenetic changes that occur during development, a multi-institutional group of scientists, including several from the Salk Institute for Biological Studies, has discovered how modifications in key epigenetic markers influence human embryonic stem cells as they differentiate into specialized cells in the body. The findings were published May 9 in Cell.
Our findings help us to understand processes that occur during early human development and the differentiation of a stem cell into specialized cells, which ultimately form tissues in the body, says co-lead author Joseph R. Ecker, a professor and director of Salks Plant Molecular and Cellular Biology Laboratory and holder of the Salk International Council Chair in Genetics.
Scientists have established that the gene expression program encoded in DNA is carried out by proteins that bind to regulatory genes and modulate gene expression in response to environmental cues. Growing evidence now shows that maintenance of this process depends on epigenetic marks such as DNA methylation and chromatin modifications, biochemical processes that alter gene expression as cells divide and differentiate from embryonic stem cells into specific tissues. Epigenetic modificationscollectively known as the epigenomecontrol which genes are turned on or off without changing the letters of the DNA alphabet (A-T-C-G), providing cells with an additional tool to fine-tune how genes control the cellular machinery.
In their study, the Salk researchers and their collaborators from several prominent research institutions across the United States examined the beginning state of cells, before and after they developed into specific cell types. Starting with a single cell typethe H1 human embryonic stem cell, the most widely studied stem cell line to datethe team followed the cells epigenome from development to different cell states, looking at the dynamics in changes to epigenetic marks from one state to another. Were they methylated, an essential process for normal development, or unmethylated? What happened to the cells during development? What regulatory processes occurred in the cell lineage?
The scientists found sections of the DNA that activate regulatory genes, which in turn control the activity of other genes, tend to have different amounts of letters of the DNA alphabet, C and G specifically, depending on when these regulatory genes are turned on during development. Additionally, regulatory genes that control early development are often located on stretches of DNA called methylation valleys, or DMVs, that are generally CG rich and devoid of epigenetic chemical modifications known as methylation. Consequently, these genes have to be regulated by another epigenetic mechanism, which the authors found were chemical changes called chromatin modifications. Chromatin is the mass of materialDNA and proteinsin a cells nucleus that helps to control gene expression.
On the other hand, genes active in more mature cells whose tissue type is already determined tend to be CG poor and regulated by DNA methylation. The results suggest that distinct epigenetic mechanisms regulate early and late states of embryonic stem cell differentiation.
Epigenomic studies of how stem cells differentiate into distinct cell types are a great way to understand early development of animals, says Ecker, who is also a Howard Hughes Medical Institute and Gordon and Betty Moore Foundation Investigator. If we understand how these cells lineages originate, we can understand if something goes right or wrong during differentiation. Its a very basic study, but there are implications for being able to produce good quality cell types for various therapies.
Read more from the original source:
Salk researchers chart epigenomics of stem cells that mimic early ...
Stem Cell Therapy for Knees, Osteoarthritis and Autoimmune Disorders: King Goff Discusses Treatment
King Goff received three applications of his own adipose tissue-derived stem cells over the course of 3 days for a knee injury and autoimmune issues at the S...
By: cellmedicine
Continued here:
Stem Cell Therapy for Knees, Osteoarthritis and Autoimmune Disorders: King Goff Discusses Treatment - Video
University of Adelaide researchers are working on a stem cell project they hope will lead to a new treatment for multiple sclerosis (MS).
They have started a three-year project using adult stem cells to directly target the damaged site in the central nervous system (CNS).
Multiple sclerosis is an autoimmune inflammatory disease of the brain and spinal cord.
To control the disease, effective treatments need to control the immune response and repair damage to nerve-protection sheaths.
'We've already shown adult stem cells have great potential to control the immune response and promote repair of the central nervous system,' says Professor Shaun McColl in a statement timed to coincide with Kiss Goodbye to MS month. He said the trick was to get the stem cells to the right location.
'We aim to show we can modify stem cells to more effectively reach the central nervous system, and that we can use these cells to inhibit inflammation.
'If it works, there is great potential for a new therapy for this debilitating disease.'
Read more here:
Bid for MS breakthrough
LONDON--(BUSINESS WIRE)--
Cell Medica today announced the treatment of the first patient in the ASPIRE Trial, an early stage Phase I/II clinical study investigating the safety and efficacy of CytovirTM ADV for the treatment of adenovirus infections in immunosuppressed pediatric patients following bone marrow transplantation.
The ASPIRE Trial represents a collaborative R&D project among Cell Medica, UCL Institute of Child Health and the Great Ormond Street Hospital for Children. The project is funded in part by a grant from the Technology Strategy Board, the UKs innovation agency.
Cytovir ADV is under development as a new way to treat adenovirus infections in pediatric patients following allogeneic hematopoietic stem cell (bone marrow) transplantation. These patients are profoundly immunosuppressed for a period of three to six months after the procedure and therefore highly vulnerable to serious infections. In certain high risk pediatric groups following bone marrow transplantation, there is a mortality risk of up to 30% for patients developing adenovirus infections. No drug is currently approved for the treatment of adenovirus infections in this patient group.
Cytovir ADV is comprised of naturally occurring T lymphocyte cells (T cells) which demonstrate immune response functions when exposed to adenovirus antigens. The ASPIRE Trial will explore whether adenovirus-specific T cells can be infused in pediatric patients to reconstitute immediate and long-lasting immunity against the virus, thereby potentially avoiding the medical costs, hospitalization and mortality associated with adenovirus infections in this patient group.
The ASPIRE Trial will include up to 15 patients and is expected to complete in early 2015. The Chief Investigator is Dr. Waseem Qasim of the UCL Institute of Child Health.
Extending the pipeline of patient-specific T cell therapies for immune reconstitution
Cytovir ADV is an extension of Cell Medicas T cell products being investigated for infections in patients following bone marrow transplantation. Cell Medicas lead product, Cytovir CMV, is currently being tested in two randomized controlled studies across 15 transplantation centres in the UK.
Gregg Sando, CEO of Cell Medica, commented: The ASPIRE Trial initiates the clinical development of Cytovir ADV in pediatric patients following bone marrow transplantation. Along with Cytovir CMV, we are developing the adenovirus treatment to expand our cell therapy solutions to include two of the most important viral infections in patients following bone marrow transplantation. The clinical research partnership with the UCL Institute of Child Health and the Great Ormond Street Hospital has been very productive in allowing us to identify a high risk group of pediatric patients who could gain particular benefit from an effective and non-toxic antiviral treatment. The support of the Technology Strategy Board was instrumental to provide the platform for this successful collaboration.
Notes to Editors
The rest is here:
Cell Medica Announces Treatment of First Pediatric Patient in Early Stage Clinical Trial of Cytovir ADV